Oxidized <scp>LDL</scp> Induces Pro‐Inflammatory Transcriptomic and Epigenomic Responses in Human <scp>CD4</scp> <sup>+</sup> T Cells
Elevated circulating low-density lipoprotein cholesterol (LDL-C) is a key risk factor for coronary artery disease (CAD). The pathogenesis of CAD is multifactorial, driven by heritable and lifestyle-related risk factors. Although CD4<sup>+</sup> T cells are one of the main cell types in atherosclerotic lesions, their interaction with atherogenic oxidized LDL (ox-LDL) remains poorly understood. Therefore, we sought to characterize the transcriptomic and epigenomic consequences of ox-LDL on activated human CD4<sup>+</sup> T cells. We find that ox-LDL causes a shift towards a pro-inflammatory, cytokine-producing CD4<sup>+</sup> T cell transcriptomic state. Concurrently, ox-LDL induces genome-wide changes in chromatin accessibility, notably in promoter regions. By integrating our multiomic data, we identify the NRF1 and SP1 transcription factors as likely mediators of ox-LDL-induced changes in gene expression. In contrast, the influence of AP-1 related factors over CD4<sup>+</sup> T cell gene expression decreases following ox-LDL stimulation. We leveraged our multiomic data to investigate the disease relevance of ox-LDL exposure, by investigating genomic locations where CAD-associated single nucleotide polymorphisms were found within dynamic ox-LDL-regulated accessible chromatin regions. Together, we demonstrate a disease-relevant role for ox-LDL in atherogenic conditioning of CD4<sup>+</sup> T cells. Understanding such cell-type specific interactions with CAD risk factors may facilitate the development of targeted therapies for CAD.
Authors
- Anil Chalisey
- Jiahao Jiang
- Toby A. Brown
- Chris A. O'Callaghan
Institutions
- Centre for Human Genetics (GB)
- University of Oxford (GB)
Publication Details
- Journal
- The FASEB Journal
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1096/fj.202503657r
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- British Heart Foundation